Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerDavid Miles, Gilles Romieu, Arlene Chan et al.|Journal of Clinical Oncology|2010Cited by 887
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Andreas Schneeweiß et al.|Annals of Oncology|2021Cited by 724
Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast CancerStephen Chan, P. Fumoleau, Gilles Romieu et al.|Journal of Clinical Oncology|2009Cited by 119
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130H. S. Rugo, Leisha A. Emens, Sherene Loi et al.|Annals of Oncology|2019Cited by 115
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)Mohamed A. Gouda, Vivek Subbiah, Filip Jankú et al.|Annals of Oncology|2023Cited by 103